Safety labeling on generic drugs is inconsistent, study says

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8650 (Published 21 December 2012)
Cite this as: BMJ 2012;345:e8650

Recent rapid responses

Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on bmj.com. Although a selection of rapid responses will be included as edited readers' letters in the weekly print issue of the BMJ, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window.

Displaying 1-1 out of 1 published

Editor,

Also in the EU differences between generic medicinal products and their originators exist. Many older products have several originators in various memberstates and often the product informations are not harmonised. These differences naturally extend to their generics.

Another reason is data protection. If the originator gets an additional indication approved, this is protected and the new indication must not be listed in the product information. This is unfortunately also the case for safety-information generated during this so called line-extension. There are situations where this is appropriate, eg. in case of higher doses for particular indications. Often this is legally required nonsense.

Competing interests: None declared

Marcus Müllner, Head of agency

Austrian Medicines and Medical Devices Agency, Traisengasse 5, 1200 Vienna, Austria

Click to like:

THIS WEEK'S POLL